metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P- 30 CLINICAL FEATURES, TREATMENT, AND SURVIVAL OF PATIENTS WITH BUDD-CHIARI SY...
Información de la revista
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Acceso a texto completo
P- 30 CLINICAL FEATURES, TREATMENT, AND SURVIVAL OF PATIENTS WITH BUDD-CHIARI SYNDROME IN A HEPATOLOGY COLOMBIAN CENTER
Visitas
246
Ximena Morales1, Daniel Rojas1, Felipe Durán-Torres2, Carolina Salinas3, Leonardo Pérez3, Andrés Murillo3, Enrique Ponce3, Jorge Ceballos3, Martín Garzón3, Geovanny Hernández-Cely3, Cristina Torres4, Adriana Varón4, Andrés Murcia5, Gilberto Mejía5, José Gabriel Caviedes5, Juan Manuel Pérez5, Oscar Beltrán3,4,6
1 Fellow Gastroenterology and Digestive Endoscopy. LACARDIO/ Cardioinfantil Foundation - Universidad del Rosario. Bogotá, Colombia
2 Epidemiologist - Universidad del Rosario. Bogotá, Colombia
3 Department of Gastroenterology, LACARDIO/ Cardioinfantil Foundation. Bogotá, Colombia
4 Department of Hepatology - LACARDIO / Cardioinfantil Foundation. Bogota, Colombia
5 Department of Hepatobiliary Surgery- LACARDIO/ Cardioinfantil Foundation. Bogota, Colombia
6 Department of Interventional Radiology- LACARDIO/ Cardioinfantil Foundation. Bogotá, Colombia
Este artículo ha recibido
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 28. Núm S1

Abstracts of the 2022 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

Budd-Chiari syndrome is defined as the obstruction of the hepatic venous flow. In Colombia, there is limited evidence regarding the characterization of these patients. This study aims to describe the clinical features, management, and survival of these patients in a Colombian hepatology reference center. This study aimed to describe the clinical features, management, and survival of patients diagnosed with Budd-Chiari Syndrome at a Colombian Hospital from 2010 to 2021.

Materials and Methods

A retrospective descriptive longitudinal study of a cohort of patients with Budd-Chiari syndrome. Adult patients diagnosed with Budd-Chiari Syndrome were included. A descriptive analysis of the data was carried out.

Results

A total of 31 patients diagnosed with Budd-Chiari syndrome were included. 58.1% (n=18) were women. The median age was 27 years [interquartile range (IQR) 23-27]. Ascites was the main clinical manifestation (87.1%, n=27). At the time diagnosis was made, 48.4% (n=15) were cirrhotic. Acquired thrombophilia was the main prothrombotic risk factor (48.4%, n=15), with the antiphospholipid syndrome as the most frequent cause (73.3%). The principal location of the outflow obstruction was in the hepatic veins (73.3%, n=22). 48.3% (n=14) had a Class II Rotterdam score (intermediate prognosis). 80.6% (n=25) were on anticoagulation. A transjugular intrahepatic portosystemic shunt (TIPS) was placed in 6 patients (19.4%), and five patients received liver transplants (16.1%). 25.8% (n=8) died. The median time from diagnosis to death was 337.1 days [interquartile range (IQR) 46.5-647.5].

Conclusions

Budd-Chiari syndrome is an infrequent disease poorly described in Colombia. This study shows that this population has similar risk factors, clinical features, and mortality as it is described in other cohorts.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos